Summit Trail Advisors
ONCE

Summit Trail Advisors’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Summit Trail Advisors’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-495
Closed -$41K – 504
2018
Q2 		$41K Buy
+495
New +$38.2K 0.01% 323
2018
Q1 		– Sell
-115
Closed -$6K – 1985
2017
Q4 		$6K Buy
+115
New +$8.26K ﹤0.01% 1389

Other funds holding ONCE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Summit Trail Advisors's ONCE Position: Q3 2018 in Review

Summit Trail Advisors sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q3 2018, closing a stake of 495 shares — an estimated $41K sold.

Summit Trail Advisors first reported a position in ONCE in Q4 2017 and held it in 2 quarters. The position peaked at $41K in Q2 2018. 176 funds tracked by Wall St. Rank hold ONCE as of Q3 2018.

  • Summit Trail Advisors reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Summit Trail Advisors sold 495 Spark Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $41K.
  • Summit Trail Advisors first reported a position in Spark Therapeutics, Inc. Common Stock in Q4 2017 and held it in 2 quarters.
  • Summit Trail Advisors's Spark Therapeutics, Inc. Common Stock position peaked at $41K in Q2 2018.
  • 176 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Summit Trail Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.